1383561-29-2 Usage
Uses
Used in Oncology:
Cabazitaxel-d6 is used as an anticancer agent for the treatment of castration-resistant prostate cancer. It acts as a microtubule inhibitor, preventing cell division and promoting cell death, making it a valuable tool in the fight against this aggressive form of cancer.
Used in Pharmaceutical Research and Development:
Cabazitaxel-d6 serves as an internal standard in the quantification of Cabazitaxel using GCor LC-mass spectrometry. This application is crucial for ensuring the accuracy and reliability of Cabazitaxel measurements in various pharmaceutical research and development processes, including drug formulation, quality control, and pharmacokinetic studies.
Used in Drug Delivery Systems:
While not explicitly mentioned in the provided materials, Cabazitaxel-d6 could potentially be used in the development of novel drug delivery systems to improve the bioavailability, targeting, and therapeutic outcomes of Cabazitaxel in cancer treatment. This application would be similar to the use of Gallotannin in drug delivery systems, as mentioned in the example.
Check Digit Verification of cas no
The CAS Registry Mumber 1383561-29-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,8,3,5,6 and 1 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1383561-29:
(9*1)+(8*3)+(7*8)+(6*3)+(5*5)+(4*6)+(3*1)+(2*2)+(1*9)=172
172 % 10 = 2
So 1383561-29-2 is a valid CAS Registry Number.
1383561-29-2Relevant academic research and scientific papers
MULTI-ARM POLYMERIC PRODRUG CONJUGATES OF TAXANE-BASED COMPOUNDS
-
Paragraph 0227, (2016/09/12)
Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of taxane-based compounds and/or fluorinated forms thereof. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the taxane-based compound is achieved.
DEUTERATED AND/OR FLUORINATED TAXANE DERIVATIVES
-
Page/Page column 42, (2012/07/13)
The invention relates to (among other things) deuterated and/or fluorinated docetaxel and cabazitaxel and derivatives thereof, as well as compositions comprising each of the foregoing.
